Clinical Trial Update: Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study evaluating TG02 Citrate in patients with advanced hematologic malignancies has completed, including AML, ALL, blast crisis, MDS, and multiple myel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia in Blast Crisis
• Multiple Myeloma
• Myelodysplastic Syndrome

Drugs mentioned

• TG02 Citrate (TG02)

Snippet

Sponsor: Tragara Pharmaceuticals, Inc. | Conditions: AML, ALL | Phase 1 | Status: COMPLETED